KIF22

Across TCGA pan-cancer cohorts, KIF22 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KIF22 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher KIF22 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated KIF22 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and UCEC are the cancer types where KIF22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	All	0.892	0.563	.002	22	view →
LUAD	DFS	Tertile	III,IV	0.940	0.422	.004	18	view →
UCEC	OS	Quartile	II,III,IV	1.000	0.437	.021	6	view →
HNSC	OS	Median	All	0.800	0.876	.048	2	view →
PDAC	OS	Median	II,III,IV	1.000	0.825	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KIF22–LSCC (DFS)

Open the LSCC breakdown →